Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes

Umberto Gianelli, Nicola Stefano Fracchiolla, Agostino Cortelezzi, Caterina Pellegrini, Federica Savi, Alessia Moro, Maria Grazia Grimoldi, Giorgio Lambertenghi Deliliers, Guido Coggi, Silvano Bosari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Apoptosis has a crucial role in myelodysplastic syndromes (MDS), being responsible of the ineffective hematopoiesis characteristic of the disease. Apoptosis rate is elevated in "early phase" MDS, whereas it diminishes during disease progression to acute leukemia, consensually to the acquisition of independent growth features. Survivin is a member of the inhibitor of the apoptosis (IAP) family, with the bifunctional role of suppressing apoptosis while facilitating cell cycle progression. We investigated Survivin mRNA levels by real-time quantitative reverse transcriptase PCR analysis and Survivin protein expression by immunohistochemistry in 49 bone marrow (BM) aspirates and in 17 BM biopsies (BMB) from MDS patients. Survivin mRNA levels were higher in MDS than in control group (1.68 ± 1.46 vs 0.25 ± 0.22; p > 0.0001). MDS patients with low or INT1 International Scoring System for Evaluating Prognosis (IPSS) displayed higher levels of Survivin mRNA in comparison to INT2 or high IPSS (1.91 ± 1.51 vs 0.88 ± 0.95; p = 0.0058). Survivin protein immunoreactivity was evaluated as Survivin index S (i) and calculated according to the formula: S (i) = % of Survivin positive cells × BMB cellularity/100. Survivin index was higher in the MDS group than in normal BM (p = 0.05). Moreover, in eight cases in which BM aspirates and trephine biopsy were available, we found a significant association between the level of Survivin mRNA and protein expression (p = 0.011). In conclusion, this study demonstrates increased levels of Survivin in MDS compared to normal controls. Moreover, higher levels of transcripts are related to "low-risk" MDS. Our results suggest an active role of Survivin in normal and in myelodysplastic hematopoiesis.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalAnnals of Hematology
Volume86
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Myelodysplastic Syndromes
Bone Marrow
Apoptosis
Messenger RNA
Hematopoiesis
Biopsy
Proteins
Reverse Transcriptase Polymerase Chain Reaction
Disease Progression
Cell Cycle
Leukemia
Immunohistochemistry
Control Groups
Growth

Keywords

  • Immunohistochemistry
  • Myelodysplastic syndromes
  • Real-time RT-PCR
  • Survivin

ASJC Scopus subject areas

  • Hematology

Cite this

Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes. / Gianelli, Umberto; Fracchiolla, Nicola Stefano; Cortelezzi, Agostino; Pellegrini, Caterina; Savi, Federica; Moro, Alessia; Grimoldi, Maria Grazia; Deliliers, Giorgio Lambertenghi; Coggi, Guido; Bosari, Silvano.

In: Annals of Hematology, Vol. 86, No. 3, 03.2007, p. 185-189.

Research output: Contribution to journalArticle

Gianelli, Umberto ; Fracchiolla, Nicola Stefano ; Cortelezzi, Agostino ; Pellegrini, Caterina ; Savi, Federica ; Moro, Alessia ; Grimoldi, Maria Grazia ; Deliliers, Giorgio Lambertenghi ; Coggi, Guido ; Bosari, Silvano. / Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes. In: Annals of Hematology. 2007 ; Vol. 86, No. 3. pp. 185-189.
@article{989d684dd6e74ee6a000896cfa11274a,
title = "Survivin expression in {"}low-risk{"} and {"}high-risk{"} myelodysplastic syndromes",
abstract = "Apoptosis has a crucial role in myelodysplastic syndromes (MDS), being responsible of the ineffective hematopoiesis characteristic of the disease. Apoptosis rate is elevated in {"}early phase{"} MDS, whereas it diminishes during disease progression to acute leukemia, consensually to the acquisition of independent growth features. Survivin is a member of the inhibitor of the apoptosis (IAP) family, with the bifunctional role of suppressing apoptosis while facilitating cell cycle progression. We investigated Survivin mRNA levels by real-time quantitative reverse transcriptase PCR analysis and Survivin protein expression by immunohistochemistry in 49 bone marrow (BM) aspirates and in 17 BM biopsies (BMB) from MDS patients. Survivin mRNA levels were higher in MDS than in control group (1.68 ± 1.46 vs 0.25 ± 0.22; p > 0.0001). MDS patients with low or INT1 International Scoring System for Evaluating Prognosis (IPSS) displayed higher levels of Survivin mRNA in comparison to INT2 or high IPSS (1.91 ± 1.51 vs 0.88 ± 0.95; p = 0.0058). Survivin protein immunoreactivity was evaluated as Survivin index S (i) and calculated according to the formula: S (i) = {\%} of Survivin positive cells × BMB cellularity/100. Survivin index was higher in the MDS group than in normal BM (p = 0.05). Moreover, in eight cases in which BM aspirates and trephine biopsy were available, we found a significant association between the level of Survivin mRNA and protein expression (p = 0.011). In conclusion, this study demonstrates increased levels of Survivin in MDS compared to normal controls. Moreover, higher levels of transcripts are related to {"}low-risk{"} MDS. Our results suggest an active role of Survivin in normal and in myelodysplastic hematopoiesis.",
keywords = "Immunohistochemistry, Myelodysplastic syndromes, Real-time RT-PCR, Survivin",
author = "Umberto Gianelli and Fracchiolla, {Nicola Stefano} and Agostino Cortelezzi and Caterina Pellegrini and Federica Savi and Alessia Moro and Grimoldi, {Maria Grazia} and Deliliers, {Giorgio Lambertenghi} and Guido Coggi and Silvano Bosari",
year = "2007",
month = "3",
doi = "10.1007/s00277-006-0215-0",
language = "English",
volume = "86",
pages = "185--189",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes

AU - Gianelli, Umberto

AU - Fracchiolla, Nicola Stefano

AU - Cortelezzi, Agostino

AU - Pellegrini, Caterina

AU - Savi, Federica

AU - Moro, Alessia

AU - Grimoldi, Maria Grazia

AU - Deliliers, Giorgio Lambertenghi

AU - Coggi, Guido

AU - Bosari, Silvano

PY - 2007/3

Y1 - 2007/3

N2 - Apoptosis has a crucial role in myelodysplastic syndromes (MDS), being responsible of the ineffective hematopoiesis characteristic of the disease. Apoptosis rate is elevated in "early phase" MDS, whereas it diminishes during disease progression to acute leukemia, consensually to the acquisition of independent growth features. Survivin is a member of the inhibitor of the apoptosis (IAP) family, with the bifunctional role of suppressing apoptosis while facilitating cell cycle progression. We investigated Survivin mRNA levels by real-time quantitative reverse transcriptase PCR analysis and Survivin protein expression by immunohistochemistry in 49 bone marrow (BM) aspirates and in 17 BM biopsies (BMB) from MDS patients. Survivin mRNA levels were higher in MDS than in control group (1.68 ± 1.46 vs 0.25 ± 0.22; p > 0.0001). MDS patients with low or INT1 International Scoring System for Evaluating Prognosis (IPSS) displayed higher levels of Survivin mRNA in comparison to INT2 or high IPSS (1.91 ± 1.51 vs 0.88 ± 0.95; p = 0.0058). Survivin protein immunoreactivity was evaluated as Survivin index S (i) and calculated according to the formula: S (i) = % of Survivin positive cells × BMB cellularity/100. Survivin index was higher in the MDS group than in normal BM (p = 0.05). Moreover, in eight cases in which BM aspirates and trephine biopsy were available, we found a significant association between the level of Survivin mRNA and protein expression (p = 0.011). In conclusion, this study demonstrates increased levels of Survivin in MDS compared to normal controls. Moreover, higher levels of transcripts are related to "low-risk" MDS. Our results suggest an active role of Survivin in normal and in myelodysplastic hematopoiesis.

AB - Apoptosis has a crucial role in myelodysplastic syndromes (MDS), being responsible of the ineffective hematopoiesis characteristic of the disease. Apoptosis rate is elevated in "early phase" MDS, whereas it diminishes during disease progression to acute leukemia, consensually to the acquisition of independent growth features. Survivin is a member of the inhibitor of the apoptosis (IAP) family, with the bifunctional role of suppressing apoptosis while facilitating cell cycle progression. We investigated Survivin mRNA levels by real-time quantitative reverse transcriptase PCR analysis and Survivin protein expression by immunohistochemistry in 49 bone marrow (BM) aspirates and in 17 BM biopsies (BMB) from MDS patients. Survivin mRNA levels were higher in MDS than in control group (1.68 ± 1.46 vs 0.25 ± 0.22; p > 0.0001). MDS patients with low or INT1 International Scoring System for Evaluating Prognosis (IPSS) displayed higher levels of Survivin mRNA in comparison to INT2 or high IPSS (1.91 ± 1.51 vs 0.88 ± 0.95; p = 0.0058). Survivin protein immunoreactivity was evaluated as Survivin index S (i) and calculated according to the formula: S (i) = % of Survivin positive cells × BMB cellularity/100. Survivin index was higher in the MDS group than in normal BM (p = 0.05). Moreover, in eight cases in which BM aspirates and trephine biopsy were available, we found a significant association between the level of Survivin mRNA and protein expression (p = 0.011). In conclusion, this study demonstrates increased levels of Survivin in MDS compared to normal controls. Moreover, higher levels of transcripts are related to "low-risk" MDS. Our results suggest an active role of Survivin in normal and in myelodysplastic hematopoiesis.

KW - Immunohistochemistry

KW - Myelodysplastic syndromes

KW - Real-time RT-PCR

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=33846686544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846686544&partnerID=8YFLogxK

U2 - 10.1007/s00277-006-0215-0

DO - 10.1007/s00277-006-0215-0

M3 - Article

C2 - 17124585

AN - SCOPUS:33846686544

VL - 86

SP - 185

EP - 189

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -